Lansoprazole microgranules suspension
P-GI05-109
Phase 3 small_molecule completed
Quick answer
Lansoprazole microgranules suspension for Gastroesophageal Reflux Disease is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Gastroesophageal Reflux Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed